Gabelli Asset ETF GAST 深 滬
等待開盤 04-01 09:30:00 美东时间
32.2791
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 32.2791
- 總市值 645.58万
- 52周最高 33.637
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 22.3524
- 委 比 0.00%
- 總股本 20.00万
- 歷史最高 33.637
- 量 比 0
- 振 幅 0.00%
- 歷史最低 18.2622
- 每 手 1
- 風險率 2.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Qiagen Receives U.S. Clearance For Gastrointestinal Panels On Fully Automated Qiastat-Dx Rise Syndromic Testing System
BRIEF-Qiagen Receives U.S. Clearance For Gastrointestinal Panels On Fully Automated Qiastat-Dx Rise Syndromic Testing System March 11 (Reuters) - QIAGEN NV QIA.DE : SAID ON TUESDAY: RECEIVES U.S. CLEARANCE FOR GASTROINTESTINAL PANELS ON FULLY AUTOMATED QIASTAT-DX RISE SYNDROMIC TESTING SYSTEM Source
03-11 14:18
BRIEF-Claudia Gast Will Join General Motors As Deputy CFO
BRIEF-Claudia Gast Will Join General Motors As Deputy CFO Feb 9 (Reuters) - General Motors Co GM.N : GM: CLAUDIA GAST IS JOINING GENERAL MOTORS ON MARCH 1 AS DEPUTY CFO AND VICE PRESIDENT, STRATEGY, CORPORATE DEVELOPMENT, AND TECHNOLOGY PARTNERSHIPS Source text: [ID:] Further company coverage: GM.N
02-10 04:12
BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio
Dec 12 (Reuters) - Arcus Biosciences Inc RCUS.N: ARCUS PROVIDES UPDATE ON PHASE 3 STAR-221 STUDY AND CONCENTRATES ITS RESEARCH AND DEVELOPMENT INVESTMENT ON CASDATIFAN AND EMERGING INFLAMMATION AND IM...
2025-12-12 21:39
BRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 Study
Dec 12 (Reuters) - Gilead Sciences Inc GILD.O: GILEAD: DISCONTINUATION OF PHASE 3 STAR-221 STUDY GILEAD: DISCONTINUATION DECISION BASED ON RECOMMENDATION FROM INDEPENDENT DATA MONITORING COMMITTEE GIL...
2025-12-12 21:30
BRIEF-Chimeric Therapeutics Says CDH17 Granted FDA Orphan Drug Designation For Gastric Cancer
Dec 8 (Reuters) - Chimeric Therapeutics Ltd CHM.AX: CDH17 GRANTED FDA ORPHAN DRUG DESIGNATION FOR GASTRIC CANCER Further company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))
2025-12-08 08:55
BRIEF-Conmed Corp - Announces Exit From Gastroenterology Product Lines
Dec 5 (Reuters) - Conmed Corp CNMD.N: CONMED CORP - ANNOUNCES EXIT FROM GASTROENTEROLOGY PRODUCT LINES CONMED CORP - COMPANY EXPECTS EPS DILUTION OF $0.45-$0.55 IN 2026 CONMED CORP - REAFFIRMS 2025 RE...
2025-12-05 21:01
BRIEF-Positive Herizon-GEA-01 Phase 3 Results Support Ziihera As Her2-Targeted Agent-Of-Choice And Ziihera Combination Regimens As New Standard Of Care In First-Line Her2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
Nov 17 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O: POSITIVE HERIZON-GEA-01 PHASE 3 RESULTS SUPPORT ZIIHERA® (ZANIDATAMAB-HRII) AS HER2-TARGETED AGENT-OF-CHOICE AND ZIIHERA COMBINATION REGIMENS AS NEW...
2025-11-17 19:04
BRIEF-ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology
Oct 22 (Reuters) - Prophase Labs Inc PRPH.O: PROPHASE LABS ANNOUNCES STUDY VALIDATING BE-SMART ESOPHAGEAL CANCER TEST ACCEPTED BY JOURNAL OF CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Source text: ID:nG...
2025-10-22 19:32
BRIEF-Arcus Bioscience Announces First Overall Survival Results From Phase 2 Edge-Gastric Study
Oct 12 (Reuters) - Arcus Biosciences Inc RCUS.N: ANTI-TIGIT DOMVANALIMAB PLUS ANTI-PD-1 ZIMBERELIMAB AND CHEMOTHERAPY SHOWED 26.7 MONTHS OF MEDIAN OVERALL SURVIVAL AS FIRST-LINE TREATMENT OF UNRESECTA...
2025-10-13 06:10
华盛早报 | 英伟达、甲骨文、AMD只是开始？OpenAI还有大交易！“IPO超购王”金叶国际今日上市
英伟达、甲骨文、AMD只是开始？OpenAI还有大交易！“IPO超购王”金叶国际今日上市，暗盘一度暴涨880%；谁是下一任美联储主席？这4个人最有希望>>
2025-10-10 08:25
